HDAC9 and autosomal dominant polycystic kidney disease: A recent high-throughput screening platform for polycystic kidney disease drug discovery, utilising both murine and human ADPKD models, has also identified HDAC inhibitors as having differential responses between Pkd1 mutant and wildtype cells [65].